Transforming medicine

Alessandro Della Chà Appointed as Director of Generics UK

Generics Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Generics Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Generics Announces UK FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Generics Wins BEL Small Company of the Year 2019

Generics Announces Planned CFO Succession

Generics Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.

Generics Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Generics Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement

Generics’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

Notice of Annual General Meeting

Generics Receives Complete Response Letter from FDA for BARHEMSYS®

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

Results for the year ended 31 December 2018

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

Supportive Cardiac Safety Data for BARHEMSYS™

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

Generics Resubmits BARHEMSYS™ New Drug Application